Support pediatric brain cancer patients: donate to End Brain Cancer Initiative, connect families to specialists, and discover new FDA-approved treatments.
Support pediatric brain cancer patients: donate to End Brain Cancer Initiative, connect families to specialists, and discover new FDA-approved treatments.
Support pediatric brain cancer research and increase patient access to treatments with the End Brain Cancer Initiative during Childhood Cancer Awareness Month.
Support pediatric cancer patients by donating to the End Brain Cancer Initiative, which connects patients to the top specialists and researchers in the US.
Jazz Pharmaceuticals has announced the U.S. FDA's approval of Modeyso™ (dordaviprone), the first and only treatment for pediatric brain cancer.
September is Childhood Cancer Awareness Month. Join EBCI by honoring and advocating for children who have been effected by cancer and the families who care for them.
Tovorafenib has received FDA approval for treating low-grade glioma in children.
(Courtesy of ASCO FDA Alerts) tovorafenib FDA Approval for LGG On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. […]
In a groundbreaking development for pediatric oncology, Oncoheroes Biosciences, Inc. has received the FDA's green light to proceed with two crucial clinical trials. This milestone opens the door to exploring potential drug treatments for young cancer patients, offering newfound hope in the fight against childhood cancer. The U.S. Food and Drug Administration (FDA) recently granted […]
